Overview of Entera Bio and OPKO Health's Partnership
Entera Bio Ltd. (NASDAQ: ENTX) and OPKO Health, Inc. (NASDAQ: OPK) have reached an exciting milestone in their collaboration aimed at creating innovative treatments for obesity and metabolic disorders. The companies have unveiled promising topline results from their pharmacokinetic and pharmacodynamic (PK/PD) studies, particularly highlighting their oral oxyntomodulin treatment.
Insights Into the PK/PD Study
This partnership revolves around a unique long-acting oxyntomodulin analog developed by OPKO, which is paired with Entera’s specialized N-Tab™ technology. The goal of this study is to pave the way for the first oral dual agonist targeting both GLP-1 and glucagon, which could allow patients the convenience of a once-daily tablet. Oxyntomodulin, a hormone released from the small intestine, plays a crucial role in controlling appetite and supporting weight loss efforts.
Significant Findings in Animal Models
Through rigorous research, Entera and OPKO carried out in vivo PK/PD studies in rodent and pig models. The results were noteworthy, revealing impressive systemic exposure from just a single oral dose of oxyntomodulin in both types of models. Particularly, the pig model showed a significant increase in plasma concentrations over an extended duration, similar to semaglutide, which is the only approved oral GLP-1 analog currently available.
Pharmacological Effects and Next Steps
A glucose tolerance test conducted on rats demonstrated the effectiveness of oxyntomodulin, showing a statistically significant decrease in plasma glucose levels after glucose was administered, compared to a placebo. These positive results reinforce the promising trajectory of the program, leading to upcoming presentations at clinical conferences.
Insights from Leadership
Miranda Toledano, the CEO of Entera, expressed her excitement regarding the collaboration with OPKO, stating, “The bioavailability and pharmacological data we are gathering are crucial for advancing toward our IND-enabling efforts.”
Background and Market Overview
Previously, OPKO disclosed results from their pegylated oxyntomodulin, which facilitated weight loss in a Phase 2B clinical trial involving 113 individuals with obesity and diabetes. Continuous improvements to the oxyntomodulin agonist are underway to enhance its effectiveness while maintaining its long-acting properties. Notably, there are currently no approved oxyntomodulin agents on the market, as most competing products are either small molecules or require injections.
About Entera Bio
Entera is a clinical-stage company focused on creating oral peptide therapies designed to meet critical medical needs. At the heart of their approach is the N-Tab™ platform. With an exciting lineup of developments, Entera is poised to enter clinical trials for five unique oral peptide programs by 2025. Their leading candidate, EB613 (oral PTH (1-34)), is particularly promising as it aims to transform the treatment landscape for post-menopausal women at risk of osteoporosis. Having achieved encouraging results from a Phase 2 study, they are now preparing for a Phase 3 registrational trial to further validate this innovative therapy.
About OPKO Health
OPKO Health is a dynamic biopharmaceutical company striving to secure a leading role in rapidly growing markets through its deep expertise in discovery, development, and commercialization. Their dedication to innovation shines through in their advancements in diagnostics and integrated medicine solutions.
Frequently Asked Questions
What is the focus of Entera Bio and OPKO Health's collaboration?
The partnership aims to develop an oral dual agonist for GLP-1 and glucagon to effectively address obesity and metabolic disorders.
What were the results of the PK/PD studies?
The studies revealed significant systemic exposure from a single oral dose and showed encouraging pharmacological effects in animal models.
How does oxyntomodulin function?
Oxyntomodulin is a peptide hormone that assists in reducing appetite and promoting weight loss, playing a vital role in metabolic regulation.
What is Entera Bio’s leading product candidate?
Entera’s leading candidate is EB613, an oral PTH (1-34) being positioned as a new therapy for osteoporosis.
What future plans do Entera and OPKO have?
The companies are set to present their findings from the PK/PD studies at upcoming clinical conferences and are focused on advancing their therapy toward regulatory approval.
